{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:46:04Z","timestamp":1787600764198,"version":"build-2736575974"},"reference-count":83,"publisher":"Academy of Managed Care Pharmacy","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.18553\/jmcp.2026.32.7.832","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:52:53Z","timestamp":1782323573000},"page":"832-846","source":"Crossref","is-referenced-by-count":1,"title":["Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease"],"prefix":"10.18553","volume":"32","author":[{"given":"Blessing I.","family":"Okoye","sequence":"first","affiliation":[{"name":"Health Outcomes Division, College of Pharmacy, The University of Texas at Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie C.","family":"Barner","sequence":"additional","affiliation":[{"name":"Health Outcomes Division, College of Pharmacy, The University of Texas at Austin"},{"name":"TxCORE, College of Pharmacy, The University of Texas at Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeun Ah","family":"Kang","sequence":"additional","affiliation":[{"name":"Health Outcomes Division, College of Pharmacy, The University of Texas at Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Richards","sequence":"additional","affiliation":[{"name":"Health Outcomes Division, College of Pharmacy, The University of Texas at Austin"},{"name":"TxCORE, College of Pharmacy, The University of Texas at Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10233"},{"key":"r2","unstructured":"National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: Expert panel report, 2014. Accessed July 15, 2025. https:\/\/www.nhlbi.nih.gov\/health-topics\/evidence-based-management-sickle-cell-disease"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02545-7"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177988"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2009.12.022"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21807"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006281"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168856"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006940"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.44546"},{"key":"r11","unstructured":"U.S Food and Drug Administration. FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns. September 2024. Accessed January 15, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15396"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.14740\/jh1127"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24587"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26765"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22134"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21968"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1225-7"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2016.01.001"},{"key":"r21","unstructured":"Udeze C, Jerry M, Evans K, Li N, Jain S, Andemariam B. Adherence, treatment use, and clinical outcomes in patients with sickle cell disease with recurrent vaso-occlusive crises treated with L-glutamine, voxelotor, or crizanlizumab in the United States. European Hematology Association. 2024. Accessed July 30, 2025. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419570\/chuka.udeze.adherence.treatment.use.and.clinical.outcomes.in.patients.with.html"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8296139"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26021"},{"issue":"5","key":"r24","first-page":"123","volume":"10","author":"Migotsky M","year":"2022","journal-title":"Pharmacy (Basel)"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035400"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000972620.97090.b5"},{"key":"r27","volume-title":"Medicaid and CHIP Sickle Cell Disease Report, T-MSIS Analytic Files (TAF) 2017","author":"Wilson-Frederick S","year":"2021"},{"key":"r28","doi-asserted-by":"crossref","unstructured":"Gondhi JP, Dombkowski KJ, Scott EL, Reeves SL. The impact of sickle cell anemia and mental health diagnoses on healthcare use and preventive care among children enrolled in Medicaid, 2005-2012.\n                      J Pediatr.\n                      2020;224:79-86.e2. doi:10.1016\/j.jpeds.2020.05.027","DOI":"10.1016\/j.jpeds.2020.05.027"},{"issue":"2","key":"r29","first-page":"PCC.10m01063","volume":"13","author":"Jerrell JM","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55070385"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14070"},{"key":"r32","unstructured":"Wilson-Frederick S, Hulihan M, Blaz J, Young BM. Prevalence of sickle cell disease among Medicare fee-for-service beneficiaries, age 18-75\u00a0years, in 2016. 2019. Accessed August 2, 2025. https:\/\/www.cms.gov\/About-CMS\/Agency-Information\/OMH\/Downloads\/Data-Highlight-15-Sickle-Cell-Disease.pdf"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142463"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.04.002"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsac068"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e31815ff5c5"},{"issue":"11","key":"r37","first-page":"1090","volume":"101","author":"Edwards CL","year":"2009","journal-title":"J Natl Med Assoc"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2011.01.010"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-207"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18981"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.36906"},{"key":"r42","unstructured":"CDC. Data and Statistics on Children\u2019s Mental Health | Children\u2019s Mental Health. Accessed September 23, 2025. https:\/\/www.cdc.gov\/children-mental-health\/data-research\/index.html"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1002\/icd.70008"},{"key":"r44","unstructured":"Center for behavioral health statistics and quality SA and MHSAS. Substance abuse and mental health services administration (2024). Key substance use and mental health indicators in the United States: results from the 2023 National survey on drug use and health. 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47095\/National%20Report\/National%20Report\/2023-nsduh-annual-national.pdf"},{"key":"r45","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7224a1"},{"key":"r46","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"r47","doi-asserted-by":"publisher","DOI":"10.1111\/jphs.12111"},{"key":"r48","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1347092"},{"key":"r49","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.21.2497"},{"key":"r50","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4772"},{"key":"r51","unstructured":"Cells S, Mpa EA, Jalowsky M, et al. Medicaid access & landscape review for prescription drugs treating sickle cell disease. 2022. Accessed August 9, 2025. https:\/\/sickcells.org\/wp-content\/uploads\/2024\/04\/2023-Medicaid-Access-and-Landscape-Review-for-SCD.pdf"},{"key":"r52","unstructured":"Policy statement: Depression screening. American Academy of Child & Adolescent Psychiatry. 2019. Accessed August 13, 2025. https:\/\/www.aacap.org\/AACAP\/Policy_Statements\/2019\/Policy_Statement_on_Depression_Screening.aspx"},{"key":"r53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j603"},{"key":"r54","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.4530"},{"key":"r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2015.09.002"},{"key":"r56","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1771"},{"key":"r57","unstructured":"US Food and Drug Administration. FDA approves crizanlizumab-tmca for sickle cell disease. Accessed August 9, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizanlizumab-tmca-sickle-cell-disease"},{"key":"r58","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.3.227"},{"key":"r59","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20413"},{"key":"r60","unstructured":"American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. 2019. Accessed August 15, 2025. https:\/\/www.apa.org\/depression-guideline"},{"key":"r61","unstructured":"DeAngelis T. Mental illness and violence: Debunking myths, addressing realities. American Psychological Association. Accessed July 11, 2025. https:\/\/www.apa.org\/monitor\/2021\/04\/ce-mental-illness"},{"key":"r62","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202100661"},{"key":"r63","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12772"},{"key":"r64","doi-asserted-by":"publisher","DOI":"10.4097\/kja.19087"},{"key":"r65","doi-asserted-by":"publisher","DOI":"10.1097\/NNR.0b013e31827bf533"},{"key":"r66","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012083"},{"key":"r67","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000054"},{"key":"r68","first-page":"1","volume":"527","author":"Brody DJ","year":"2025","journal-title":"NCHS Data Brief"},{"key":"r69","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20230215-01"},{"key":"r70","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.00805"},{"key":"r71","unstructured":"Simpson S. Medicaid\u2019s lower payout a turnoff for Texas mental health providers.\n                      The Texas Tribune\n                      . Accessed October 1, 2025. https:\/\/www.texastribune.org\/2023\/04\/28\/texas-mental-health-medicaid\/"},{"key":"r72","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2015.02.004"},{"key":"r73","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.11.1412"},{"key":"r74","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q020"},{"key":"r75","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0417-0"},{"issue":"1","key":"r76","first-page":"63","volume":"3","author":"Liu X","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"key":"r77","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800275"},{"key":"r78","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.2.223"},{"key":"r79","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-009-9277-5"},{"key":"r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2011.04.002"},{"key":"r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2014.02.002"},{"key":"r82","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000361"},{"key":"r83","unstructured":"Medicaid. Eligibility Policy. Accessed August 30, 2025. https:\/\/www.medicaid.gov\/medicaid\/eligibility-policy\/index.html"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:55:26Z","timestamp":1782323726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.7.832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.18553\/jmcp.2026.32.7.832"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.7.832","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}